MIER2

Across TCGA pan-cancer cohorts, MIER2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MIER2 data layer compared with 21 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher MIER2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MIER2 expression acts as an unfavorable survival marker.

BRCA, COAD, and CESC are the cancer types where MIER2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	DFS	Median	All	0.238	0.903	<.001	36	view →
COAD	DFS	Median	All	0.126	0.784	<.001	20	view →
CESC	OS	Median	III,IV	0.095	0.755	<.001	18	view →
KIRP	OS	Median	All	0.199	0.903	<.001	15	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MIER2–BRCA (DFS)

Open the BRCA breakdown →